Search

Your search keyword '"Ramji, Alnoor"' showing total 252 results

Search Constraints

Start Over You searched for: Author "Ramji, Alnoor" Remove constraint Author: "Ramji, Alnoor" Publication Type Academic Journals Remove constraint Publication Type: Academic Journals
252 results on '"Ramji, Alnoor"'

Search Results

1. Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis

2. Velacur ACE outperforms FibroScan CAP for diagnosis of MASLD.

6. Association of hepatitis B virus treatment with all-cause and liver-related mortality among individuals with HBV and cirrhosis: a population-based cohort study

7. Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses

8. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

9. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

10. A global research priority agenda to advance public health responses to fatty liver disease

11. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries

12. Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study

13. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection

14. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection

16. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

19. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

20. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study

22. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

23. Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study

24. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

25. O- 23 STRATEGIES TO ELIMINATE HEPATITIS C VIRUS INFECTION IN THE AMERICAS

33. A phase 2, open‐label, randomized, multiple‐dose study evaluating Inarigivir in treatment‐naïve patients with chronic hepatitis B.

34. Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA).

36. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)

37. Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis

38. Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders.

39. Chronic hepatitis C infection is associated with higher incidence of extrahepatic cancers in a Canadian population based cohort.

41. THU-207 - Ethnic disparity in mortality related to extrahepatic manifestations among people with chronic HCV infection: a large, linked administrative population-based study in British Columbia, Canada

44. FRI-151 - Strategies to eliminate hepatitis C virus infection in the Americas

48. Patient‐specific genetic factors predict treatment failure in sofosbuvir‐treated patients with chronic hepatitis C.

49. Twelve- or 16-Week Treatment With Daclatasvir Combined With Peginterferon Alfa and Ribavirin for Hepatitis C Virus Genotype 2 or 3 Infection: Command GT2/3 Study: 762

Catalog

Books, media, physical & digital resources